Clinical trial: Oral zinc in hepatic encephalopathy

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 9, 2010, Pages 1080-1090

  Takuma, Y ^a,b   Nousot, K ^c   Makino, Y ^b   Hayashi, M ^b   Takahashi, H ^b  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

^b IWAKUNI NATIONAL HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRANCHED CHAIN AMINO ACID; DIURETIC AGENT; ISOLEUCINE; LACTULOSE; LEUCINE; LIVACT; POLAPREZINC; UNCLASSIFIED DRUG; VALINE; ZINC;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; LIVER CIRRHOSIS; MALE; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN RESTRICTION; QUALITY OF LIFE; SHORT FORM 36; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NITROGEN; QUALITY OF LIFE; TREATMENT OUTCOME; ZINC;

EID: 78449271709     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04448.x     Document Type: Article

References (44)

1. Butterworth RF. Pathogenesis and treatment of portal-systemic encephalopathy: an update. Dig Dis Sci 1992; 37: 321-7.
2. Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004; 39: 739-45.
3. Conn HBJ. Hepatic Encephalopathy: Syndromes and Therapies. Bloomington, Illinois: Medi-Ed Press, 1994.
4. Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45: 549-59.
5. Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double blind, randomized trial. Gastroenterology 2003; 124: 1792-801.
6. Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 705-13.
7. Hayashi M, Ohnishi H, Kawade Y, Muto Y, Takahashi Y. Augmented utilization of branched-chain amino acids by skeletal muscle in decompensated live cirrhosis in special relation to ammonia detoxication. Gastroenterol Jpn 1981; 16: 64-70.
8. Horst D, Grace ND, Conn HO, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 1984; 4: 279-87.
9. Van der Rijt CC, Schalm SW, Schat H, Foeken K, De Jong G. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991; 100:1114-8.
10. Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996; 23: 1084-92.
11. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomized controlled trial. Lancet 1984; 2: 493-5.
12. Grüngreiff K, Presser HJ, Franke D, et al. Correlations between zinc, amino acids and ammonia in liver cirrhosis. Z Gastroenterol 1989; 27: 731-5.
13. Dejong CH, Deutz NE, Soeters PB. Muscle ammonia and glutamine exchange during chronic liver insufficiency in the rat. J Hepatol 1994; 21:299-307.
14. Rabbani P, Prasad A. Plasma ammonia and liver ornithine transcarbamoylase activity in zinc-deficient rats. Am J Physiol 1978; 235: E203-6.
15. Yoshida Y, Higashi T, Nouso K, et al. Effects of zinc deficiency ? zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis. Acta Med Okayama 2001; 55: 349-55.
16. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
17. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
18. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72: 573-83.
19. Conn HO. Trailmaking and numberconnection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977; 22: 541-50.
20. Lezak MD. A compendium of tests and assessment techniques. In: Lezak MD, ed. Neuropsychological Assessment. New York: Oxford University Press, 1995:381-4.
21. Kato A, Kato M, Ishii H, et al. Development of quantitative neuropsychological tests for diagnosis of subclinical hepatic encephalopathy in liver cirrhosis patients and establishment of diagnostic criteriamulticenter collaborative study in Japanese. Hepatol Res 2004; 30: 71-8.
22. Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1045-53.
23. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998; 51: 1037-44.
24. Marchesini G, Bianchi G, Amodio P, et al. Italian Study Group for quality of life incirrhosis. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001; 120: 170-8.
25. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 1992; 30: 473-83.
26. Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998; 51:903-12.
27. Dawson B, Trapp R. Basic and Clinical Biostatistics. 4th ed. USA: McGraw Hill, 2004.
28. Hayashi M, Ikezawa K, Ono A, et al. Evaluation of the effects of combination therapy with branched-chain amino acid and zinc supplements on nitrogen metabolism in liver cirrhosis. Hepatol Res 2007; 37: 615-9.
29. Katayama K. Ammonia metabolism and hepatic encephalopathy. Hepatol Res 2004; 30S: 73-80.
30. Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26: 1410-4.
31. Dhiman RK, Sawhney MS, Chawla YK, et al. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000; 45: 1549-52.
32. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-81.
33. Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003; 48: 1622-6.
34. Younossi ZM, Boparai N, Price LL, et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001; 96: 2199-205.
35. Saab S, Ibrahim AB, Shpaner A, et al. MELD fails to measure quality of life in liver transplant candidates. Liver Transpl 2005; 11: 218-23.
36. Kalaitzakis E, Josefsson A, Bjornsson E. Type and etiology of liver cirrhosis are not related to the presence of hepatic encephalopathy or health-related quality of life: a cross-sectional study. BMC Gastroenterol 2008; 8: 46.
37. Moriwaki H, Miwa Y, Tajika M, et al. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun 2004; 313: 405-9.
38. Hara K, Yonezawa K, Weng QP, et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998; 273: 14484-94.
39. Sano H, Furuta S, Toyama S, et al. Study on the metabolic fate of catena-(S)-[mu-[N alpha-(3-aminopropionyl) histidinato(2-)-N1,N2,O:N tau]-zinc]. 1st communication:absorption, distribution, metabolism and excretion after single administration to rats. Arzneimittelforschung 1991; 41:965-75.
40. Nishimura Y, Yamagishi Y, Ando K, Saito T, Matsukura T. L-Carnosine and close derivatives accelerate zinc uptake from the intestine in rats. Biomedical Res Trace Elements 2001; 12: 159-67.
41. Nagamine T, Takagi H, Takayama H, et al. Preliminary study of combination therapy with interferon-a and zinc in chronic hepatitis C patients with genotype 1b. Biol Trace Elem Res 2000;75: 53-63.
42. Younossi ZM, Grryatt G, Kiwi M, Moparai N, King D. Development of a disease-specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45:295-300.
43. Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a doubleblind crossover trial. Dig Dis Sci 1991;36: 1204-8.
44. Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med 1993; 2: 414-6.